Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine.

AUTOR(ES)

Farr, M

RESUMO

Hepatotoxicity is a rare complication of sulphasalazine therapy in ulcerative colitis. This report describes two rheumatoid patients in whom raised serum levels of liver enzymes occurred soon after starting sulphasalazine treatment for their arthritis. In both cases the serum enzyme levels returned to normal after stopping the drug. Drug-induced hepatotoxicity should be considered in patients with rheumatoid arthritis (RA) who develop raised serum levels of liver enzymes while taking sulphasalazine.

Documentos Relacionados

• Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.
• Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.
• Raised serum alkaline phosphatase in rheumatoid disease. An index of liver dysfunction?
• Serum alkaline ribonuclease derived from vascular endothelial cells is raised in patients with rheumatoid vasculitis.
• Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.